Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Macimorelin

Our opinion on this compoundEstablished, active research

52/100

Approved oral GH secretagogue with strong diagnostic evidence but narrow research frontier appeal

Look, macimorelin has a genuinely impressive regulatory pedigree. It’s the first and only oral agent approved by both the FDA (December 2017) and EMA (January 2019) specifically for adult growth hormone deficiency diagnosis, displacing the insulin tolerance test as the clinical reference standard in many centers. That’s a real achievement in drug development. The problem, from a research standpoint, is that it basically solved a diagnostic problem and then stopped being interesting as a frontier target.

The mechanism is solid but not exciting. GHS-R1a agonism is mature pharmacology at this point. Macimorelin’s main trick is peptidomimetic design: Fehrentz and Martinez at Montpellier took the hexarelin scaffold and used alpha-aminoisobutyric acid capping plus two indole-containing side chains to create something orally bioavailable and protease-resistant. Thats genuinely good medicinal chemistry. But it’s not a novel mechanism. The receptor is well-characterized, the downstream GH pulse is predictable, and the diagnostic sampling window at 45 and 90 minutes post-dose is clean precisely because there are no pharmacological surprises.

Where macimorelin earns its score is evidence quality and translational signal within the diagnostic indication. The Garcia 2013 phase 2 and Garcia 2018 phase 3 pivotal trial showed sensitivity and specificity competitive with the ITT without the hypoglycemia risk. Yuen et al. (2021) refined diagnostic cutoffs and validated the approach further. That’s multi-center, well-replicated, regulatory-grade data. Herodes et al. (2023) ran a cancer cachexia pilot that generated some early signal, and there’s preclinical work in seizure models and neuroprotection worth watching. None of those secondary programs are anywhere close to the clinical rigor of the approved diagnostic evidence base.

Differentiation is genuinely high inside the diagnostic niche: no competing compound holds this regulatory status for AGHD. But bench investigators using GHS-R1a agonists as tools usually reach for ipamorelin, ghrelin itself, or MK-677 first, depending on the question. Macimorelin’s oral bioavailability is practically convenient, but the receptor pharmacology doesnt unlock biology that injection-route secretagogues can’t reach. It’s a cleaner clinical tool than a uniquely powerful research probe.

We think macimorelin belongs in any program centered on AGHD diagnostics, pediatric GH axis assessment, or ITT-comparison methodology. The cachexia follow-on data is worth a second look, and the neuroprotective preclinical angle is real, if thin. Outside those lanes, it’s a solved problem. A serious bench scientist interested in GHS-R1a biology has better-explored tools. The score reflects a compound that did exactly what it set out to do and is now living in a well-lit but narrow corridor of the literature.

Novelty

35

Mechanism promise

40

In-category differentiation

62

Evidence quality

68

Translational signal

65

Research bench value

50

Rationale Macimorelin earns solid evidence and translational scores because it is a genuinely approved diagnostic drug with clean phase 3 data, but GHS-R1a agonism is mature pharmacology and the compound’s differentiation is tightly confined to the AGHD diagnostic niche; outside that lane it offers no special probe value over ipamorelin or ghrelin itself, which keeps novelty and mechanism scores low and pulls the overall into the low fifties.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic peptidomimetic growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

An orally active peptidomimetic ghrelin receptor agonist developed at the University of Montpellier and advanced by Aeterna Zentaris as the first and only approved oral diagnostic test for adult growth hormone deficiency, distinguished from other growth hormone secretagogues by its validated diagnostic application and favorable safety profile relative to the insulin tolerance test.

Abstract

Macimorelin (JMV-1843, EP-1572, AEZS-130), a synthetic peptidomimetic agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor), is the first and only orally administered diagnostic agent approved by the United States Food and Drug Administration (December 2017) and the European Medicines Agency (January 2019) for the evaluation of adult growth hormone deficiency (AGHD). The compound was invented and first synthesized at the University of Montpellier and the Centre National de la Recherche Scientifique (CNRS) in France by Fehrentz, Martinez, Guerlavais, and colleagues as part of a structure-activity program seeking orally bioavailable growth hormone secretagogues derived from the hexarelin scaffold, and was subsequently licensed to Aeterna Zentaris for clinical development and marketed under the trade names Macrilen (United States, Novo Nordisk) and Ghryvelin (European Union, Consilient Health and subsequently Pharmanovia) [1, 2]. Structurally, macimorelin is a modified tripeptide containing two indole (tryptophan-derived) moieties linked through a central peptidomimetic backbone with a terminal formamide group and an N-terminal alpha-aminoisobutyric acid cap, conferring oral bioavailability and resistance to proteolytic degradation that distinguish it from the earlier peptide-based growth hormone secretagogues such as GHRP-6 and hexarelin.

The compound binds the GHS-R1a receptor on pituitary somatotroph cells with an IC50 of 22.9 nanomolar in human pituitary tissue and activates the Gq/11-phospholipase C signaling cascade, stimulating endogenous growth hormone release into the systemic circulation in a manner pharmacologically analogous to the endogenous ligand ghrelin [2, 3]. Following oral administration at the diagnostic dose of 0.5 mg/kg body weight, macimorelin produces a robust and reproducible rise in serum growth hormone concentration that peaks between 30 and 90 minutes post-dose, permitting diagnostic discrimination between growth hormone-sufficient and growth hormone-deficient adults through serial blood sampling over a 90-minute test window. The Phase 3 confirmatory trial (Garcia et al., 2018) in 157 adults demonstrated 87 percent sensitivity and 96 percent specificity at a growth hormone cutoff of 2.8 ng/mL, with 97 percent reproducibility on repeat testing, establishing macimorelin as a clinically validated alternative to the insulin tolerance test with the practical advantages of oral administration, absence of hypoglycemia risk, and a shorter, simpler test protocol [4, 5].

Pharmacokinetics are characterized by rapid oral absorption (median time to peak plasma concentration approximately 0.75 hours), hepatic metabolism predominantly through cytochrome P450 3A4 (CYP3A4) to a partially active O-demethylated metabolite, a terminal elimination half-life of approximately 4.1 hours, approximately 70 percent plasma protein binding, and predominantly fecal excretion [6, 7]. Food substantially reduces both the rate and extent of absorption (Cmax reduction of approximately 55 percent, AUC reduction of approximately 44 to 49 percent with a high-fat meal), mandating overnight fasting before the diagnostic test. The principal drug interaction concern is with strong CYP3A4 inducers (which may reduce macimorelin exposure and produce false-positive diagnostic results) and strong CYP3A4 inhibitors (which may elevate exposure). The compound produces a mean increase in the corrected QT interval of approximately 11 milliseconds at the diagnostic dose, requiring avoidance of concomitant QT-prolonging medications during the test [8].

Adverse events in clinical trials were mild and transient, with dysgeusia (bitter or metallic taste), dizziness, headache, nausea, fatigue, hunger, and diarrhea reported at low frequencies. No serious adverse events attributable to macimorelin were reported in the pivotal trials across more than 1000 administered subjects [5, 8]. The compound is administered as a single diagnostic dose rather than as a chronic therapeutic regimen, and the safety profile reflects this acute exposure context. Beyond the diagnostic indication, macimorelin has been investigated in cancer cachexia (pilot trial demonstrating safety and numerical weight improvement) and in pharmacoresistant epilepsy (preclinical seizure suppression through GHS-R1a-mediated neuroprotection), though the compound is not approved for any therapeutic application [9, 10].

This monograph reviews the chemistry, synthesis, and structural pharmacology of macimorelin; the GHS-R1a receptor mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base across diagnostic and investigational applications; reconstitution and handling considerations; stack interactions and drug-drug interaction considerations; the adverse-event and safety signal; and a comparative assessment of five growth hormone secretagogue or diagnostic candidates (insulin tolerance test, glucagon stimulation test, anamorelin, ibutamoren, and GHRH-arginine test) against macimorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1419Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Ropivacaine

Plain-language summaryIntrigue 58 / 100

Ropivacaine (Naropin) is a single-(S)-enantiomer amide local anesthetic approved in 1996, structurally intermediate between mepivacaine (propyl, racemic) and bupivacaine (butyl, racemic). It carries the propyl chain like mepivacaine but the (S)-only purity of the modern enantiopure agents. The shorter alkyl chain reduces lipid solubility versus bupivacaine, producing the so-called motor-sparing profile: at concentrations giving equivalent sensory block, motor block is less profound. That property drives selection in obstetric epidural at low concentrations (0.0625 to 0.125 percent) where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor recovery before discharge matters. Cardiotoxicity profile is favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Maximum dose is 3 mg/kg. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A well-proven clinical anesthetic whose settled mechanism leaves little open for bench researchers

Look, ropivacaine is a genuinely good drug. The (S)-enantiomer selectivity, the motor-sparing behavior at low epidural concentrations, the reduced cardiotoxicity versus racemic bupivacaine: these are real pharmacological advantages that earned the compound a permanent spot in clinical practice over three decades. But “real advantages that matter clinically” and “compelling bench research target” aren’t the same thing, and thats the tension here.

The mechanism is voltage-gated sodium channel block with state-dependent kinetics. That mechanism was understood before ropivacaine existed. The enantiomeric toxicity separation emerged from work in the late 1980s recognizing that R-enantiomers of long-acting amide anesthetics carried most of the cardiac toxicity burden. Astra synthesized ropivacaine as a direct, deliberate response to that understanding. The science was incremental and ultimately successful. But from a 2026 vantage point, there’s nothing left to discover about why ropivacaine works or how it differs from bupivacaine. That question is closed.

The differentiation story within local anesthetics is legitimate. Motor-sparing at 0.0625 to 0.125 percent epidural concentrations is real and operationally important in obstetric analgesia and ambulatory peripheral nerve block. But levobupivacaine covers most of the same safety story, and for any genuine mechanistic study of NaV channel pharmacology, there are far more informative tools: isoform-selective toxins, synthetic channel modulators, state-selective inhibitors built specifically for probe work. Ropivacaine is a clinical comparator, not an investigator’s instrument.

The evidence base is excellent, as it should be for an approved drug entering its fourth decade of use. Multiple controlled trials, well-characterized pharmacokinetics, clear LAST risk at high cumulative doses, lipid emulsion rescue protocols established. We think that high evidence quality on a settled question doesn’t generate bench research value; it closes it. The interesting work in local anesthetic research right now is elsewhere: liposomal and extended-release formulations, subtype-selective NaV1.7 and NaV1.8 targeting for pain selectivity without motor block, and the mechanistic biology of cardiac toxicity in LAST models. Ropivacaine is background knowledge for those programs, not the center of one.

What ropivacaine doesn’t offer a bench investigator is an open question. There’s no novel indication with early signal pulling researchers back to this molecule. There’s no contested mechanism that needs resolution, no surprising second target, no mitochondrial angle or receptor crosstalk worth chasing. The compound did what it was designed to do. Scoring it high would confuse clinical utility with research interest, which is the exact error the v1 rubric made. A 41 feels right.

Novelty

18

Mechanism promise

16

In-category differentiation

38

Evidence quality

78

Translational signal

80

Research bench value

28

Rationale Ropivacaine scores well on evidence and translational signal precisely because it’s a 30-year-old approved drug, but those strengths reflect a closed research question, not an open one. Novelty, mechanism interest, and bench probe value are all low, dragging the overall to the low-40s despite clean pharmacology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amide local anesthetic (S-enantiomer propyl analog)

The (S)-propyl analog of bupivacaine and mepivacaine, marketed as Naropin, with reduced cardiotoxicity and motor-sparing sensory block profile.

Abstract

Ropivacaine ((S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 84057-95-4; molecular formula C17H26N2O; molecular weight 274.40) is an amide local anesthetic developed at AB Astra in the 1990s and approved by the FDA in 1996 (Naropin). The compound is structurally intermediate between mepivacaine (propyl chain, racemic) and bupivacaine (butyl chain, racemic): ropivacaine carries the propyl substituent like mepivacaine but is sold as a single (S)-enantiomer. The shorter alkyl chain reduces lipid solubility relative to bupivacaine, contributing to a less profound motor block at concentrations producing equivalent sensory block (the so-called motor-sparing property exploited in obstetric epidural analgesia and ambulatory regional anesthesia). The (S)-enantiomer purity confers a cardiotoxicity profile favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Onset is 5 to 15 minutes for infiltration and peripheral nerve block; duration is 3 to 6 hours, generally somewhat shorter than bupivacaine at equivalent doses. Maximum recommended dose is 3 mg/kg, with cumulative doses up to 770 mg/24 hours documented in continuous epidural analgesia. The motor-sparing profile drives ropivacaine selection in obstetric epidural at low concentrations (0.0625 to 0.125 percent) where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor function recovery before discharge is operationally important. Lipid emulsion rescue applies to any LAST event with ropivacaine as for other long-acting amides.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1311Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
NACET

Our opinion on this compoundNiche research probe

35/100

Clever prodrug chemistry that outperforms NAC on CNS delivery, but thin human evidence and saturated biology limit its scope

Look, NACET is genuinely clever prodrug chemistry and we mean that sincerely. The core idea is simple: NAC is a polar acid that struggles to cross lipid bilayers and the blood-brain barrier, so you esterify the carboxyl group, turn it into a neutral molecule at physiological pH, and let passive diffusion carry it across. Intracellular esterases cleave the ester bond, NAC is released inside the cell, and glutathione synthesis proceeds from there. The mechanism is well-understood and the pharmacological rationale is real.

The published in vitro data are consistent with the theory. Work out of USC and Italian academic groups during the 2000s reports intracellular GSH elevations of 30 to 50 percent after NACET exposure versus under 10 percent for equimolar NAC. The rodent in vivo picture is similarly supportive: oral NACET produces measurable brain GSH elevation that equimolar oral NAC simply doesnt. That’s a meaningful result, and it is the compound’s best argument for bench utility.

Here’s the thing: the evidence base stops there. No human pharmacokinetic studies of note have been published, and the clinical trial space is essentially empty. Compare that to NAC itself, which has decades of clinical data across acetaminophen overdose, mucolytic applications, and more recently psychiatric indications. NACET has better CNS delivery on paper, but better delivery of a well-understood molecule into a well-studied pathway is not the same as a novel research frontier. The underlying biology, cysteine replenishment driving glutathione synthesis, is one of the most saturated antioxidant circuits in the literature.

The differentiation picture is also muddier than it looks. NAC amide (NACA) is a direct competitor with overlapping lipophilicity and BBB-penetration arguments, and it carries some independent preclinical literature of its own. NACET is not clearly dominant over NACA on any published head-to-head metric; thats a comparison serious investigators should make before committing to a CNS oxidative stress model built around this compound.

What we like: if you’re building a rodent model of oxidative stress-driven neurodegeneration and IP NAC is your current workaround for the bioavailability problem, NACET is worth the evaluation. The esterase-mediated intracellular release is mechanistically clean and well-precedented in prodrug pharmacology. It is a legitimately better tool than plain NAC for any experiment that requires CNS GSH delivery.

What we don’t like: the literature is thin, the human data is essentially nonexistent, and the pathway is familiar territory. NACET makes NAC better. It doesn’t make the research question more interesting, and at this point in time the compound needs a serious investigator willing to generate the first rigorous human PK data before it earns a higher tier.

Novelty

38

Mechanism promise

40

In-category differentiation

40

Evidence quality

28

Translational signal

20

Research bench value

45

Rationale NACET earns credit as a CNS-penetrant glutathione delivery tool with real preclinical support, but zero human clinical data, direct competition from NAC amide, and a fundamentally well-mapped underlying pathway (cysteine-to-GSH) keep all six axes from climbing out of the low-to-mid range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Lipophilic ester of N-acetylcysteine and glutathione precursor

The ethyl ester of N-acetylcysteine, a lipophilic NAC analog with substantially higher cellular and central nervous system bioavailability than the parent acid.

Abstract

NACET (N-acetyl-L-cysteine ethyl ester; CAS 59587-09-6; molecular formula C7H13NO3S; molecular weight 191.25) is the ethyl ester prodrug of N-acetylcysteine (NAC), developed at the University of Southern California and at Italian academic groups during the 2000s as a lipophilic alternative to NAC with markedly improved cellular and central nervous system bioavailability. The parent NAC is a polar carboxylic acid with low oral bioavailability (approximately 6 to 10 percent), poor blood-brain barrier penetration, and limited intracellular accumulation; NACET is a neutral ester at physiological pH, crosses cell membranes by passive diffusion, and is hydrolyzed intracellularly by ubiquitous esterases to release NAC inside the cell. Published in vitro studies report cellular glutathione (GSH) elevation 30 to 50 percent above baseline after NACET exposure compared to less than 10 percent for equimolar NAC, owing to the difference in cellular delivery. Published rodent in vivo work reports brain GSH elevation after oral NACET that is not detectable after equimolar oral NAC, consistent with the BBB-penetration argument. The pharmacological consequence is that NACET delivers the antioxidant and glutathione-precursor activity of NAC at lower oral doses with central nervous system exposure. Reported applications in research include neuroprotection, oxidative stress modulation, and as a research tool for cysteine delivery in cell culture. Human pharmacokinetic data are limited and no large clinical trials have been published. The compound is not approved by FDA or EMA for any indication. NAC itself is approved as an antidote for acetaminophen overdose and as a mucolytic; the ester form is sold only as a research-grade compound or supplement. Stability is moderate at room temperature; refrigerated storage is preferred for solid material.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1326Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Orforglipron

Our opinion on this compoundNovel, promising

71/100

Oral small-molecule GLP-1 agonist with strong Phase 2 signal and genuine delivery differentiation

Look, the reason orforglipron matters isnt the GLP-1 biology itself. That territory has been thoroughly mapped since the early liraglutide work, and the receptor pharmacology is now among the most-studied systems in metabolic disease. What’s interesting here is that Lilly and Chugai figured out how to make a small molecule activate the GLP-1 receptor without being a peptide at all. That’s a non-trivial chemical achievement, and the implications for access and adherence are real.

The structural picture: orforglipron (LY3502970, CAS 2212020-52-3) is a C42 small molecule at ~781 Da that binds at an allosteric site distinct from the orthosteric peptide-binding pocket. This matters mechanistically because receptor activation runs through a different conformational pathway than what semaglutide or tirzepatide produce. Whether that translates to meaningfully distinct pharmacology downstream — biased agonism, different GLP-1R internalization kinetics, altered beta-arrestin recruitment — is a genuinely open question and one of the more interesting research handles on this compound right now.

On the evidence side: the 2023 Phase 2 obesity data published in NEJM are strong. Approximately 14.7 percent body weight reduction at 36 weeks at the highest dose tested, comparable to subcutaneous semaglutide and clearly ahead of oral semaglutide as deployed in clinical practice. HbA1c reduction up to 2.1 percent in the type 2 diabetes arm. Multi-center, randomized, well-powered for Phase 2. We don’t have Phase 3 readouts yet — ATTAIN and ACHIEVE are both active — and thats the honest limiting factor on the evidence axis. Strong Phase 2 signal from a single program is not the same as replicated Phase 3 confirmation.

What’s differentiated: oral semaglutide requires SNAC as an absorption enhancer, strict fasting administration, and carries real-world compliance failures because peptide oral bioavailability is fundamentally fragile. Orforglipron hits 30 to 60 percent oral bioavailability without any of that — it’s a small molecule and it behaves like one. If Phase 3 confirms the Phase 2 signal, this fills a genuine gap. The side effect profile — more rapid GI-onset at initiation compared to long-acting injectables — is worth watching in the Phase 3 data. Faster absorption means less time to titrate tolerability.

For a research program, orforglipron provides a clean probe for GLP-1R allosteric pharmacology and a mechanistically distinct comparator to peptide agonists in receptor trafficking and bias studies. We think that bench utility is real and underappreciated. What keeps the score from pushing into the low eighties is that the underlying target is GLP-1R — one of the most studied receptors in contemporary pharmacology — and single-receptor agonism, however elegant the chemistry, is a narrower pharmacological story than what the dual and triple incretins are running. Phase 3 readouts will be a meaningful inflection point.

Novelty

75

Mechanism promise

62

In-category differentiation

85

Evidence quality

65

Translational signal

72

Research bench value

60

Rationale Differentiation drives the score: orforglipron is the only oral non-peptide GLP-1R agonist in Phase 3, with Phase 2 efficacy competitive with subcutaneous semaglutide and a meaningful practical advantage over oral semaglutide’s fasting-plus-SNAC requirement. Novelty and mechanism are moderated because GLP-1R biology is now among the most extensively mapped targets in metabolic pharmacology, and allosteric small-molecule activation, while mechanistically interesting, does not redefine the receptor system the way a dual or triple agonist does.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Oral non-peptide GLP-1 receptor agonist (small molecule)

A small-molecule oral GLP-1 receptor agonist developed by Eli Lilly that does not require absorption of an intact peptide, distinguishing it from the peptide-class oral semaglutide formulation.

Abstract

Orforglipron (LY3502970; CAS 2212020-52-3; molecular formula C42H55F3N6O5; molecular weight 781.07) is a small-molecule non-peptide GLP-1 receptor agonist developed by Eli Lilly through licensing of a chemical series originated by Chugai Pharmaceutical and further optimized at Lilly. The compound is the first true small-molecule oral GLP-1 agonist to enter Phase 3 clinical trials; the only previously marketed oral GLP-1 agonist is the peptide-class oral semaglutide (Rybelsus), which requires the SNAC absorption-enhancer formulation and a strict fasted-state administration protocol owing to the intrinsically poor oral bioavailability of peptide GLP-1 agonists. The non-peptide structure of orforglipron eliminates the absorption challenge: oral bioavailability is approximately 30 to 60 percent without absorption enhancers and without strict fasting requirements; the compound is an allosteric agonist that binds at a site distinct from the GLP-1 peptide binding pocket, producing receptor activation through a non-peptide chemical scaffold. Phase 2 obesity results published in 2023 reported approximately 14.7 percent body weight reduction at 36 weeks at the highest dose, comparable to subcutaneous semaglutide and meaningfully greater than oral semaglutide at clinically used doses. Phase 2 type 2 diabetes results showed glycated hemoglobin reduction up to 2.1 percent at the highest dose. The compound is in active Phase 3 development in obesity (ATTAIN program) and type 2 diabetes (ACHIEVE program) with anticipated regulatory submissions in 2025 to 2026. Side effect profile parallels other GLP-1 agonists (nausea, vomiting, diarrhea) with somewhat more rapid onset of adverse events at initiation, attributed to the rapid absorption profile of the small molecule versus the slow titration enabled by long-acting injectable peptides. Orforglipron represents a category-shifting development in the GLP-1 class: oral, simple administration, and competitive efficacy.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1343Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Mepivacaine

Plain-language summaryIntrigue 45 / 100

Mepivacaine (Carbocaine, Polocaine) is the methyl-substituted parent of the pipecoloxylidide family that includes bupivacaine and ropivacaine. Introduced in the late 1950s by Bo af Ekenstam at AB Bofors. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of its family, with onset in 3 to 5 minutes and duration of 2 to 3 hours. Two niches in current practice: dental anesthesia (the 3 percent plain solution avoids epinephrine when the vasoconstrictor is contraindicated, and the duration matches typical procedure length), and ambulatory orthopedic spinal anesthesia where shorter duration than bupivacaine permits earlier ambulation. Sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine. Lipid emulsion rescue applies as for any local anesthetic systemic toxicity event. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

A mature amide local anesthetic with solid clinical utility and no compelling research frontier

Look, mepivacaine does exactly what it says. It blocks voltage-gated sodium channels, it’s been doing that since Bo af Ekenstam synthesized it at AB Bofors in the 1950s, and the clinical literature on it is about as settled as pharmacology gets. That’s the problem from a research standpoint. The mechanism is textbook Na+ channel inactivation, shared by every amide local anesthetic on the shelf. Theres no secondary target, no interesting receptor cross-talk, no emerging biology to chase.

The structural story is genuinely interesting at a chemistry level: the N-methyl substituent on the piperidine ring makes mepivacaine the shortest-acting member of the pipecoloxylidide family, parent to both bupivacaine and ropivacaine. That methyl group reduces lipid solubility relative to bupivacaine, which is why cardiotoxicity sits in a safer intermediate range and why duration tops out at 2 to 3 hours. Understanding that series helped establish how lipophilicity governs duration and toxicity across the class. Good history. Not current research.

Its clinical niches are real and defensible. The 3 percent plain solution occupies a specific slot in dental anesthesia where epinephrine is contraindicated, and the intermediate duration maps well to typical dental procedure length without leaving patients numb for hours. In ambulatory orthopedic spinal anesthesia, mepivacaine’s shorter duration relative to bupivacaine permits earlier ambulation and discharge, which matters operationally. The absence of a para-aminobenzoic acid metabolite separates it from the ester class and makes it usable in patients who react to ester agents. These are practical advantages, not research advantages.

As a bench tool, mepivacaine competes poorly. Investigators studying voltage-gated Na+ channels reach for tetrodotoxin, saxitoxin, or specific Nav subtype blockers with real probe selectivity. Mepivacaine is pan-Nav, low selectivity, widely available, and offers nothing mechanistically that lidocaine or bupivacaine doesn’t also provide. The racemate status means you’re not even getting the cleaner pharmacology that ropivacaine’s S-enantiomer offers in stereochemistry studies.

We dont see a compelling research program that specifically requires mepivacaine. If you’re studying Na+ channel pharmacology, better probes exist. If you’re studying the pipecoloxylidide scaffold, bupivacaine and ropivacaine carry more interesting current literature. Mepivacaine earns its place in the dental chair, not on the bench. Score reflects that honestly: high evidence for an approved, well-characterized agent, but low novelty and mechanism interest that drags the overall into the low thirties where a mature clinical workhorse belongs.

Novelty

10

Mechanism promise

12

In-category differentiation

30

Evidence quality

75

Translational signal

65

Research bench value

25

Rationale Mepivacaine scores low on novelty and mechanism because it’s a 1950s Na+ channel blocker in a mechanistically saturated class; differentiation is modest (a real but narrow niche in dental and ambulatory spinal). Evidence and translational scores are legitimately high for an approved, well-characterized clinical agent, but those gains don’t rescue the overall because there’s no research angle a serious investigator would prioritize over the dozens of more interesting compounds competing for bench time.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amide local anesthetic (intermediate-acting)

The methyl-substituted pipecoloxylidide parent of bupivacaine and ropivacaine, used in dental and orthopedic regional anesthesia.

Abstract

Mepivacaine (1-methyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 96-88-8; molecular formula C15H22N2O; molecular weight 246.35) is an amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in the same pipecoloxylidide series that produced bupivacaine and ropivacaine. The compound was introduced clinically in the late 1950s (Carbocaine, Polocaine) as a successor to lidocaine for dental and short-procedure regional anesthesia. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of the pipecoloxylidide family; lipid solubility and protein binding are intermediate between lidocaine and bupivacaine. Mechanism is voltage-gated sodium channel block. Onset is 3 to 5 minutes for infiltration; duration is 2 to 3 hours, longer with epinephrine. Maximum recommended dose is 5 mg/kg without epinephrine and 7 mg/kg with epinephrine. The principal niches in current practice are dental anesthesia (the 3 percent plain solution avoids epinephrine in patients where the vasoconstrictor is contraindicated, and the intermediate duration matches typical dental procedure length), and ambulatory orthopedic spinal anesthesia where the shorter duration relative to bupivacaine permits earlier ambulation and discharge. Mepivacaine is sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine; lipid emulsion rescue applies to LAST. The ester-class procaine and chloroprocaine are alternative short-acting infiltration agents; mepivacaine retains a market niche owing to the absence of the para-aminobenzoic acid metabolite that drives ester allergic reactions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1312Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
N-PEP-12

Our opinion on this compoundSingle-lab provenance

34/100

Oral Cerebrolysin analog with thin independent evidence and an unresolved bioavailability problem at its core

Look, N-PEP-12 is an interesting idea with a real engineering problem at its core: Cerebrolysin has about four decades of Eastern European and Asian clinical use as an IV or IM nootropic, and the operational overhead of that route is genuinely restrictive for outpatient applications. Ever Neuro Pharma’s answer was to take the same porcine brain hydrolysate, characterize the peptide fraction in the 1-10 kDa window, and package it as a daily oral capsule. That’s a legitimate R&D goal. The problem is that the solution doesn’t convincingly close the problem it set out to address.

The oral bioavailability of a peptide mixture in this size range is a real, open question that the published literature doesn’t answer. Fractions in the 1-10 kDa window face significant GI degradation; the manufacturer reports shared BDNF and IGF-1 mimetic activity in cortical neuron culture, which is the same neurotrophic framing applied to Cerebrolysin itself, but culture evidence tells you nothing about whether any active constituents survive gut transit and reach CNS concentrations that matter. Without PK data showing what actually appears in plasma — or better, CSF — after oral dosing, the activity data floats unanchored.

The clinical record for N-PEP-12 specifically consists of a small number of single-center RCTs in mild cognitive impairment and age-associated memory impairment, all within the manufacturer-sponsored published record. We’ve seen this structure before with Cerebrolysin itself, and it carries the same core limitation: the signal is real enough to be interesting but impossible to stress-test independently. Modest cognitive improvements over 90 days in MCI populations are notoriously difficult to interpret even in well-resourced multi-site trials; here thats the whole evidence base.

What we like: the oral route is a genuine differentiation play in a class where parenteral administration is the norm. If the bioavailability question were actually answered — real PK, real CNS exposure data — this would earn serious bench attention. The compound also inherits a well-characterized research lineage from Cerebrolysin, so it isn’t starting from nothing mechanistically.

What we dont like: the mechanism is essentially “neurotrophic mimetic,” which covers a lot of ground without specifying which peptide constituents are responsible for what activity, or whether any survive the gut intact. The clinical evidence is thin, single-center, and manufacturer-dominated. Cerebrolysin itself sits in the single-lab-only tier for similar reasons; N-PEP-12 has fewer trials, less replication, and an additional unanswered delivery question on top. For bench investigators who want to study complex neurotrophic preparations, Cerebrolysin is the more credible research object. N-PEP-12 is primarily a consumer-facing reformulation, and the science hasn’t caught up to the commercial ambition yet.

Novelty

40

Mechanism promise

32

In-category differentiation

42

Evidence quality

25

Translational signal

28

Research bench value

30

Rationale N-PEP-12 scores below its Cerebrolysin parent because the oral reformulation introduces a bioavailability problem the published record doesn’t resolve, and the clinical evidence is entirely single-center and manufacturer-sponsored with modest effect sizes. The oral route is a genuine differentiation angle but can’t compensate for mechanism opacity and an evidence base that resists independent evaluation.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Cerebrolysin-derived oral peptide fraction

A defined oral peptide fraction prepared from porcine brain tissue, marketed as a nutraceutical analog of intravenous Cerebrolysin for cognitive support.

Abstract

N-PEP-12 is a porcine-brain-derived peptide preparation developed by Ever Neuro Pharma (the manufacturer of Cerebrolysin) as a defined orally bioavailable analog of the parent intravenous nootropic. Cerebrolysin itself is a complex hydrolysate of porcine cerebral cortex containing approximately 25 percent free amino acids and 75 percent low-molecular-weight peptides (less than 10 kDa) administered by daily intravenous or intramuscular injection in courses of 10 to 30 days for vascular dementia, Alzheimer’s disease, ischemic stroke recovery, and traumatic brain injury indications across approximately 50 jurisdictions (Europe, Asia, Russia, South America). The intravenous administration is operationally restrictive; N-PEP-12 was developed to provide a similar peptide profile in a daily oral capsule format suitable for outpatient and over-the-counter use. The published characterization describes a peptide molecular weight distribution of 1 to 10 kDa with similar amino acid composition to Cerebrolysin and shared neurotrophic activity in cortical neuron culture (BDNF and IGF-1 mimetic effects, neurite outgrowth, protection against amyloid-beta and glutamate excitotoxicity). Clinical evidence is more limited than for Cerebrolysin: published randomized trials in mild cognitive impairment (MCI) and age-associated memory impairment report modest cognitive improvements over 90 days in single-center studies. The compound is not FDA-approved; it is marketed as a dietary supplement in the United States and as a nutraceutical or medicinal food in European jurisdictions. The principal limitation on the strength of the evidence is the small number of independent clinical trials and the dominance of the manufacturer-sponsored published record. Reconstitution is not required; oral capsules contain approximately 60 mg of peptide blend.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1329Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
SLU-PP-332

Our opinion on this compoundNovel, promising

61/100

First credible pan-ERR tool compound with striking preclinical endurance data but thin replication and no human signal yet

Look, the exercise mimetic space has a complicated history. GW501516 was the one everyone wanted – PPARδ agonism, real endurance gains in animals – and then the carcinogenicity signal killed it. AICAR works through AMPK but bioavailability is terrible for anything beyond acute injection studies. The field needed a different lever, and SLU-PP-332 is the most credible candidate that’s appeared in the past several years.

The mechanism targets the estrogen-related receptor family – ERRα, ERRβ, ERRγ – which are orphan nuclear receptors that don’t bind estrogen but share structural homology with the classical ER. What they actually do is coordinate the transcriptional response to exercise: mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, slow-twitch fiber phenotype. ERR activity is co-induced with PGC-1α, and PGC-1α is itself an ERR coactivator – there’s a feed-forward loop that exercise biology researchers have known about for years but couldn’t pharmacologically access. SLU-PP-332, from the Burris lab at Saint Louis University, is the first credible pan-isoform agonist with low-nanomolar potency across all three ERRs. That’s the differentiation story: hitting the whole family matters because ERRα and ERRγ have partially distinct target gene sets in skeletal muscle and cardiac tissue, and a selective agonist would miss that coverage.

The rodent data is striking. The headline finding – roughly doubled treadmill running time in sedentary mice at 50 mg/kg subcutaneous daily over several weeks – is the kind of number that gets attention, and the supporting gene expression data holds up: elevated COX complex subunit transcripts, mitochondrial content markers up, oxidative fiber type markers elevated. High-fat diet cohorts showed reduced fat accumulation. Older animals showed some protection against age-related muscle changes. These are coherent results that track the mechanism rather than obvious off-target pharmacology.

What we dont like: this is still almost entirely Burris lab work. Replication from independent groups is thin, and no clinical data exists. Clinical development has been announced through partner companies, but Phase 1 readouts arent public. The translational question is genuinely open – exercise transcriptional programs are well-conserved across mammals, but human pharmacokinetics, chronic tolerance windows, and the ERR family’s relationship with estrogen-sensitive tissues in long-term studies are uncharacterized. The carcinogenicity concern that ended GW501516 probably doesn’t apply mechanistically here, but nobody can say that with confidence yet.

As a bench tool, SLU-PP-332 earns its place. If you’re studying mitochondrial biology, skeletal muscle metabolism, or the molecular basis of exercise adaptation, this compound lets you pharmacologically interrogate the ERR/PGC-1α axis in ways that simply weren’t accessible before. The ERR field has been constrained for years by a lack of selective, potent agonists. That gap in the tool kit was real, and this fills it credibly. We think it warrants serious bench attention – with the appropriate skepticism a single-lab preclinical profile deserves and the understanding that the human story hasn’t started yet.

Novelty

78

Mechanism promise

78

In-category differentiation

70

Evidence quality

35

Translational signal

28

Research bench value

65

Rationale SLU-PP-332 occupies a genuinely novel mechanistic niche as a pan-isoform ERR agonist targeting the transcriptional master regulators of exercise adaptation; novelty and mechanism scores are high, but evidence quality and translational signal are constrained by single-lab preclinical origin and an absence of clinical data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pan-ERR (estrogen-related receptor) agonist exercise mimetic

A small-molecule pan-agonist of the three estrogen-related receptor isoforms (ERRα, ERRβ, ERRγ), studied as an exercise mimetic for activation of mitochondrial biogenesis and oxidative metabolism.

Abstract

SLU-PP-332 (CAS 2226909-79-9; molecular formula C25H26N2O5S; molecular weight 466.55) is a small-molecule pan-agonist of the estrogen-related receptor (ERR) family of orphan nuclear receptors developed at the Saint Louis University School of Medicine by Thomas Burris and colleagues. The ERR family comprises three isoforms (ERRalpha, ERRbeta, ERRgamma) that share substantial sequence homology with the estrogen receptor but bind distinct ligands and target distinct gene programs; the principal ERR-regulated gene programs include mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and skeletal muscle oxidative fiber phenotype. ERR activity is induced by exercise and is one of the principal transcriptional drivers of the exercise-induced metabolic adaptation phenotype, alongside PGC-1alpha (which is itself an ERR coactivator). SLU-PP-332 was characterized as an inverse partial agonist or full agonist depending on the assay, with similar potency at all three ERR isoforms (EC50 in the low-nanomolar to mid-nanomolar range). Reported in vivo effects in rodent models include increased exercise endurance (treadmill running time approximately doubled in mice receiving the compound at 50 mg/kg subcutaneous daily for several weeks without exercise training), elevation of mitochondrial gene expression in skeletal muscle, reduction of body fat mass on high-fat diet, and protection against age-related muscle dysfunction. The pharmacological profile has motivated interest in the compound as an exercise mimetic for metabolic and aging indications. The compound is research-grade and not approved by any regulatory authority; clinical development through partner companies has been announced but no Phase 1 readouts have been published as of the most recent monograph revision. Reconstitution requires DMSO or co-solvent owing to limited aqueous solubility; storage of solid material at refrigerated or frozen conditions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1344Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Anamorelin

Our opinion on this compoundEstablished, active research

57/100

First approved oral ghrelin receptor agonist for cancer cachexia with rigorous Phase 3 lean mass data but contested functional endpoints and a cardiac liability

Look, anamorelin occupies a specific and genuinely useful niche that’s easy to undervalue because ghrelin biology feels like old news. It’s not. Cancer cachexia affects roughly 20-80% of patients depending on tumor type, and the mechanistic rationale for GHSR-1a agonism here is actually solid: ghrelin receptor stimulation drives appetite, GH secretion, and lean mass accretion through a well-characterized hypothalamic-pituitary-IGF-1 axis that’s demonstrably dysregulated in cachectic patients. The compound is a full agonist at subnanomolar affinity (Ki 0.70 nM, EC50 0.74 nM) with no antagonist activity up to 1000 nM, and the oral bioavailability plus 7-12 hour half-life give it pharmacokinetic properties that endogenous ghrelin’s 30-minute half-life can’t touch.

What we like: the ROMANA trial program is one of the better-designed cachexia programs ever executed. 979 patients, 93 sites, 19 countries, randomized double-blind placebo-controlled. That level of rigor is rare in the cachexia space, which has historically been riddled with small single-center studies. The lean body mass finding is solid and replicated across ROMANA 1 and ROMANA 2 (median gains of +1.10 kg and +0.75 kg versus placebo losses in each), and the Japanese ONO-7643-04 and ONO-7643-05 studies confirmed the pattern in a different tumor spectrum and patient population. Anamorelin became the first ghrelin receptor agonist approved anywhere in the world for cancer cachexia in December 2020 and has been commercially available as Adlumiz since April 2021. That’s a real milestone in a field starved for regulatory wins.

Here’s the thing though. The EMA refusal in 2017 is not a technicality. Both ROMANA trials failed the handgrip strength co-primary endpoint, and the EMA read that as the difference between improving body composition on paper and actually improving function. Thats a fair read. The disconnect between lean mass gains and functional strength suggests the anabolic signal, while real, doesnt fully translate to meaningful physical capacity in a cachectic patient. Whether that reflects population selection, endpoint choice, or a genuine pharmacological ceiling is still an open and productive research question.

Cardiac conduction effects deserve serious attention. Approximately 10.7% of patients in Japanese registration studies showed conduction abnormalities including PR interval, QRS, and QT prolongation, and the sodium channel-blocking activity is a genuine liability that constrains the safety envelope and should inform any combination design. The pronounced food effect, a 4-fold reduction in AUC when administered with food, is also a variable you’d need to control carefully in any pharmacokinetic study. CYP3A4 interactions are well-mapped; ketoconazole co-administration increases AUC by roughly 4-fold.

For investigators, anamorelin’s value is as the reference compound for oral GHSR-1a agonism in wasting conditions. MK-677 has broader research use but no regulatory approval in cachexia specifically and a messier evidence base in oncology populations. If you’re working on cancer-associated muscle wasting, the lean mass versus function dissociation, or GH-IGF-1 axis pharmacology in a clinical context, anamorelin is the approved comparator you’d want anchoring your design. We think it sits solidly in the established-active tier: not novel, not bleeding edge, but doing real work on a real problem with unusually rigorous clinical evidence for a compound of this class.

Novelty

42

Mechanism promise

50

In-category differentiation

65

Evidence quality

70

Translational signal

63

Research bench value

55

Rationale Anamorelin earns strong evidence and translational scores from the replicated ROMANA Phase 3 program and Japanese regulatory approval, but the ghrelin receptor mechanism is well-understood rather than novel, and the EMA rejection over failed handgrip strength endpoints signals a real gap between body composition and functional benefit that limits its ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-peptidic ghrelin receptor (GHSR-1a) agonist with orexigenic, anabolic, and growth hormone secretagogue activity

A small-molecule peptidomimetic ghrelin receptor agonist developed from the Novo Nordisk growth hormone secretagogue program, approved in Japan for the treatment of cancer cachexia in non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer, and investigated in osteosarcopenia and other wasting conditions.

Abstract

Anamorelin (ONO-7643, RC-1291, ST-1291) is a non-peptidic, orally active, centrally penetrant agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a), the endogenous receptor for ghrelin. Structurally derived from peptidomimetic optimization of the growth hormone-releasing peptide scaffold at Novo Nordisk and subsequently developed by Helsinn Healthcare and Ono Pharmaceutical, anamorelin binds the ghrelin receptor with subnanomolar affinity (Ki 0.70 nM) and produces full agonist activity in fluorescence imaging plate reader (FLIPR) calcium mobilization assays with an EC50 of 0.74 nM, comparable to endogenous ghrelin (Ki 0.58 nM, EC50 0.67 nM) [1]. No antagonist activity has been observed at concentrations up to 1000 nM. The compound is distinguished from endogenous ghrelin by oral bioavailability, a plasma elimination half-life of approximately 7 to 12 hours (compared to approximately 30 minutes for ghrelin), and the absence of peptidic instability. Pharmacodynamically, a single oral dose of 100 mg produces rapid and sustained elevation of circulating growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3), with secondary increases in appetite, caloric intake, and body weight observed on chronic dosing. The principal clinical application is cancer anorexia-cachexia syndrome (CACS). Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (ROMANA 1 and ROMANA 2), conducted in 979 patients with inoperable stage III or IV non-small cell lung cancer and cachexia across 93 sites in 19 countries, demonstrated that anamorelin 100 mg daily for 12 weeks significantly increased lean body mass (median change +1.10 kg versus -0.44 kg on placebo in ROMANA 1; +0.75 kg versus -0.96 kg in ROMANA 2; both P < 0.001) and body weight, with concurrent improvement in anorexia-cachexia symptoms and quality of life measures [2]. However, both trials failed to demonstrate statistically significant improvement in the co-primary endpoint of handgrip strength, a finding that became the basis for the European Medicines Agency refusal of marketing authorization in 2017 [3]. In Japan, where a separate Phase 2 trial (ONO-7643-04) in Japanese non-small cell lung cancer patients with cachexia and a Phase 3 open-label study (ONO-7643-05) in gastrointestinal cancer cachexia confirmed lean body mass and body weight increases, anamorelin received manufacturing and marketing approval from the Pharmaceuticals and Medical Devices Agency on December 11, 2020, as the first ghrelin receptor agonist approved worldwide for cancer cachexia [4]. It is marketed as Adlumiz tablets (50 mg) by Ono Pharmaceutical and has been available since April 2021 for the treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer. Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration 0.5 to 2.0 hours), a pronounced food effect (4-fold reduction in area under the curve when administered with food), hepatic metabolism predominantly through cytochrome P450 3A4 (CYP3A4) with minor contributions from CYP2C8 and CYP2D6, and fecal excretion of approximately 92 percent of the administered dose [5, 6]. The CYP3A4 dependence produces clinically significant drug-drug interaction potential with strong CYP3A4 inhibitors (ketoconazole increases the AUC of anamorelin by approximately 4-fold). The compound depresses cardiac conduction and has sodium channel-blocking activity; prolongation of the PR interval, QRS complex, and QT interval has been observed in clinical trials, with a frequency of approximately 10.7 percent for conduction system abnormalities in Japanese registration studies [7, 8]. Contraindications include congestive heart failure, recent myocardial infarction or angina pectoris, and severe cardiac conduction defects. The most frequent adverse events are hyperglycemia (5 to 6 percent overall, substantially higher in patients with pre-existing diabetes), elevated gamma-glutamyl transpeptidase, and gastrointestinal symptoms. This monograph reviews the chemistry, synthesis, and structural pharmacology of anamorelin; the ghrelin receptor mechanism in molecular and physiological detail; comprehensive pharmacokinetics including food effect and CYP3A4 interaction; the preclinical pharmacology in rat, pig, and tumor xenograft models; the clinical evidence base across the ROMANA program, Japanese registration studies, and the osteosarcopenia indication; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five cachexia and wasting treatment candidates (ibutamoren, enobosarm, megestrol acetate, mirtazapine, and espindolol) against anamorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1417Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Octreotide

Our opinion on this compoundEstablished workhorse

52/100

The canonical SSTR2-selective reference compound, clinically mature with real bench utility but little frontier novelty

Look, octreotide is one of those compounds where the sheer weight of clinical evidence almost works against it as a research target. Bauer and colleagues at Sandoz synthesized SMS 201-995 in 1982, the FDA approved it in 1988, and by now the somatostatin receptor subtype 2 pharmacology it illuminated has been exhaustively characterized. We know the binding kinetics cold: Ki approximately 0.4 to 0.6 nanomolar at SSTR2, roughly 7 nanomolar at SSTR5, negligible at SSTR1 and SSTR4. The Gi-coupled downstream cascade, adenylyl cyclase inhibition, reduced cAMP, suppression of GH and the splanchnic peptide circus, its all textbook material at this point.

What octreotide genuinely has going for it is bench value as a reference probe. If you’re doing SSTR subtype selectivity work, you need octreotide in the comparison panel. The PROMID trial data (Rinke et al. 2009, HR 0.34, p equal to 0.000072 on time to tumor progression in midgut NETs) is clean and credible. The PK record after subcutaneous dosing, peak at 25 to 30 minutes, bioavailability near 100 percent, t1/2 roughly 90 to 120 minutes, is mature enough to serve as a reference standard for half-life extension strategies in the cyclic peptide space. The 2020 oral Mycapssa approval is genuinely interesting from a formulation-science angle, even if the compound underneath is old news.

Here’s the thing though: the research frontier in the somatostatin axis has moved. Pasireotide, with its broader SSTR1/2/3/5 profile, is the more interesting pharmacological object for investigators interested in Cushing’s disease and escape mechanisms. Lu-177 DOTATATE has repositioned the entire NET field around theranostic radiopharmaceuticals, and the octreotide scaffold underpins that ligand family as a structural starting point rather than a target in its own right. Paltusotine is the oral non-peptide SSTR2 agonist that will eventually displace octreotide in clinical maintenance, and it raises much more interesting SAR questions. Octreotide itself is mostly the molecule you reach for when you need to define what SSTR2-selective engagement looks like, not the molecule anyone is running a serious exploratory program around in 2026.

We think its place in a research library is legitimate but specific: its a comparator, a reference point, a structural ancestor. The evidence quality and translational signal scores are high because decades of human data dont lie. But the novelty and mechanism scores honestly reflect that theres very little left to discover here. Serious bench investigators in the somatostatin space will use it; they just wont be excited about it.

Novelty

22

Mechanism promise

38

In-category differentiation

50

Evidence quality

78

Translational signal

78

Research bench value

62

Rationale Octreotide scores strongly on evidence and translational signal because it is an FDA-approved drug with replicated phase 3 data and decades of clinical use, but those same facts drive novelty and mechanism scores to the floor. The compound is 40+ years old and the SSTR2 pharmacology it opened is now thoroughly characterized; the primary research question for the field has shifted to broader-subtype agents, radiolabeled conjugates, and oral non-peptide agonists, leaving octreotide as an indispensable reference probe rather than a live research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic cyclic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 and 5

A disulfide-bridged octapeptide analog of hypothalamic somatostatin-14 developed at Sandoz as SMS 201-995, distinguished from the native hormone by a 30-fold increase in inhibition of growth hormone release relative to insulin suppression and an elimination half-life extended from under 3 minutes to approximately 100 minutes after subcutaneous administration.

Abstract

Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Tabimorelin

Our opinion on this compoundNiche research probe

31/100

Discontinued oral GH secretagogue with irreversible CYP3A4 liability; retained value as a comparative SAR reference only

Look, tabimorelin represents real medicinal chemistry work. Ankersen and colleagues at Novo Nordisk took ipamorelin, already the cleanest selective GHSR peptide, and did genuine backbone reduction to produce a tripeptide-like peptidomimetic with roughly 30% oral bioavailability in dogs and a 4-hour half-life. The Phase 1 single-dose data are clean: dose-dependent GH area-under-curve, significant IGF-1 elevation at the two highest doses, a hormone response profile that looks exactly like what you expect from GHSR1a activation. Thats not nothing for an orally administered peptidomimetic in the late 1990s.

The problem is everything after Phase 1. The Phase 2 enrolled 97 adults with confirmed growth hormone deficiency in a proper multicentre RCT, and only 9 of 83 treated patients, 11 percent, cleared the 5 microgram per liter GH threshold that defines an adequate secretory response. The Novo Nordisk team understood the mechanism requires residual somatotroph capacity to function. The Phase 2 just confirmed how profoundly that capacity is depleted in the actual patient population you care about. A secretagogue cannot rescue a pituitary that lacks functional somatotrophs. This is not a tabimorelin-specific failure; it’s a ceiling problem that limits the whole secretagogue class in organic GHD. But tabimorelin is the compound where Novo Nordisk hit that ceiling and documented it cleanly.

Then there is the CYP3A4 problem, and this one really ends the story. Tabimorelin forms a quasi-irreversible complex with CYP3A4, the kind of mechanism-based inhibition that safety pharmacologists treat as a program-stopper. A single dose raises midazolam AUC by 64 percent. Seven days of dosing: 93 percent. The washout data are the most damning part: 45 percent CYP3A4 suppression persists a full week after the last dose. Macimorelin, the oral GHSR agonist that actually achieved FDA approval for GHD diagnosis, does not carry this liability. Neither does ibutamoren. Tabimorelin’s structural solution to the oral bioavailability problem came with a pharmacological cost that more successful compounds avoided.

We think there’s still a reason to study this compound, but it’s narrow. If your program is investigating why some backbone-reduced peptidomimetic GHSRPs generate P450 interactions and others don’t, tabimorelin is the reference case with the most complete clinical documentation. If you’re working on somatotroph desensitization mechanisms, the tachyphylaxis data from the 7-day Phase 1 are well-characterized and worth having. As a comparator in SAR tables for the ipamorelin-derived peptidomimetic lineage, it earns a place. For anything else, ibutamoren or macimorelin is the better starting point, and honestly there is no practical reason to run tabimorelin as a primary tool when both alternatives have cleaner profiles and deeper literature.

Novelty

32

Mechanism promise

32

In-category differentiation

15

Evidence quality

52

Translational signal

25

Research bench value

38

Rationale Scores low because Phase 2 in adult GHD returned only 11% responders, a mechanism-based CYP3A4 interaction (irreversible, persisting through 7-day washout) ended the program, and better-characterized oral GHSR agonists now define the class. Retains narrow bench utility as an SAR comparator and a documented pharmacological failure case within the peptidomimetic ghrelin agonist lineage.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally active peptidomimetic growth hormone secretagogue and ghrelin receptor (GHSR1a) agonist

A modified polypeptide derived from ipamorelin at Novo Nordisk, representing the first orally bioavailable peptidomimetic ghrelin receptor agonist advanced to Phase 2 clinical evaluation for adult growth hormone deficiency, distinguished by mechanism-based CYP3A4 inhibition and GH-axis tachyphylaxis that limited its clinical development.

Abstract

Tabimorelin (NN703; CAS 193079-69-5; molecular formula C32H40N4O3; molecular weight 528.70) is a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHSR1a, the ghrelin receptor), developed by Novo Nordisk as a non-injectable alternative to recombinant growth hormone therapy in adult growth hormone deficiency. The compound was derived from the selective pentapeptide growth hormone secretagogue ipamorelin (NNC 26-0161) through systematic backbone reduction and pharmacophore optimization conducted principally by Ankersen, Hansen, and colleagues in the late 1990s, yielding a tripeptide-like structure with oral bioavailability of approximately 30 percent in dogs and a plasma half-life of approximately 4.1 hours in the same species [1]. Tabimorelin binds the GHSR1a receptor and activates the Gq/11-coupled phospholipase C signaling cascade, producing calcium mobilization from intracellular stores, membrane depolarization, and pulsatile growth hormone release from anterior pituitary somatotroph cells. In single-dose Phase 1 studies in healthy male volunteers at doses of 0.05 to 12 mg/kg, the compound produced dose-dependent increases in growth hormone area under the curve and peak concentration, with significant elevations in GH AUC at 3.0 mg/kg (P = 0.027), 6.0 mg/kg (P = 0.0023), and 12 mg/kg (P < 0.0001), together with significant increases in insulin-like growth factor 1 (IGF-1) at the two highest dose levels [2]. In a 7-day repeated-dose Phase 1 study at four dose levels (1.71, 3.0, 4.5, and 6.86 mg/kg once daily), GH release remained significantly elevated above placebo on both days 1 and 7, but an overall significant decrease in GH release from day 1 to day 7 (P < 0.001) demonstrated tachyphylaxis at the somatotroph axis level [3]. IGF-1 and IGF binding protein 3 (IGFBP-3) increased at all dose levels, with significantly greater IGF-1 elevation at the three highest doses. The compound produced transient increases in prolactin and adrenocorticotropic hormone (ACTH) on day 1 that resolved by day 7, with no significant cortisol elevation on either assessment day [3]. The pivotal Phase 2 study enrolled 97 adults with confirmed growth hormone deficiency in a multicentre, randomized, double-blind, placebo-controlled design; only 9 of 83 NN703-treated patients (11 percent) achieved a serum peak GH concentration of 5 micrograms per liter or greater, and 1-week treatment did not significantly increase IGF-1, although IGFBP-3 was modestly elevated [4]. The limited clinical response was attributed to the severity of hypothalamic-pituitary axis disruption in the GH-deficient population, which depends on residual somatotroph capacity for a secretagogue mechanism to function. A separate clinical pharmacology investigation established that tabimorelin is a mechanism-based (irreversible) inhibitor of cytochrome P450 3A4, increasing midazolam AUC by 64 percent after a single dose and by 93 percent after 7 days of dosing, with persistent 45 percent elevation even after a 7-day washout [5]. This CYP3A4 liability, combined with the modest clinical efficacy in the target population and the GH tachyphylaxis on repeated dosing, led Novo Nordisk to discontinue clinical development. Tabimorelin remains a research-grade compound of interest for fundamental GHSR1a pharmacology, for structure-activity investigation within the peptidomimetic ghrelin agonist class, and as a comparator in the broader landscape of growth hormone secretagogues that includes ibutamoren (MK-0677), anamorelin, macimorelin, and capromorelin. The compound is not approved by any regulatory authority for human therapeutic use. It is supplied as a research-grade preparation by multiple chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1420Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026

←Previous Page

1 … 26 27 28 29 30 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.